JP2024544870A - Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用 - Google Patents

Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用 Download PDF

Info

Publication number
JP2024544870A
JP2024544870A JP2024527096A JP2024527096A JP2024544870A JP 2024544870 A JP2024544870 A JP 2024544870A JP 2024527096 A JP2024527096 A JP 2024527096A JP 2024527096 A JP2024527096 A JP 2024527096A JP 2024544870 A JP2024544870 A JP 2024544870A
Authority
JP
Japan
Prior art keywords
group
ligand compound
pharma
psma
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544870A5 (https=
JPWO2023083209A5 (https=
Inventor
ジョン，ジーユアン
ユアン，ジエンドン
イアン，ジアンタオ
ファンフー，ジェンユアン
スン，ジュアン
シー，ピン
タオ，レイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ruihe Medicine Technology Co Ltd
Original Assignee
Suzhou Ruihe Medicine Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ruihe Medicine Technology Co Ltd filed Critical Suzhou Ruihe Medicine Technology Co Ltd
Publication of JP2024544870A publication Critical patent/JP2024544870A/ja
Publication of JP2024544870A5 publication Critical patent/JP2024544870A5/ja
Publication of JPWO2023083209A5 publication Critical patent/JPWO2023083209A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024527096A 2021-11-10 2022-11-09 Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用 Pending JP2024544870A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111329108.1 2021-11-10
CN202111329108 2021-11-10
PCT/CN2022/130833 WO2023083209A1 (zh) 2021-11-10 2022-11-09 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用

Publications (3)

Publication Number Publication Date
JP2024544870A true JP2024544870A (ja) 2024-12-05
JP2024544870A5 JP2024544870A5 (https=) 2025-12-12
JPWO2023083209A5 JPWO2023083209A5 (https=) 2025-12-12

Family

ID=86335105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527096A Pending JP2024544870A (ja) 2021-11-10 2022-11-09 Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用

Country Status (9)

Country Link
US (1) US20260069725A1 (https=)
EP (1) EP4431503A1 (https=)
JP (1) JP2024544870A (https=)
KR (1) KR20240105380A (https=)
CN (1) CN118176188A (https=)
AU (1) AU2022384375A1 (https=)
CA (1) CA3237743A1 (https=)
TW (1) TW202321204A (https=)
WO (1) WO2023083209A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN117069670B (zh) * 2023-07-31 2026-04-10 复旦大学附属华山医院 靶向psma的二聚体化合物及其衍生物和应用
CN119954773A (zh) * 2023-10-31 2025-05-09 苏州威智创科生物有限公司 Psma化合物、包含其的药物组合物及其用途
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
CN118221764A (zh) * 2024-03-05 2024-06-21 苏州大学 一种双靶向分子探针及其制备方法与应用
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629201B2 (en) * 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物

Also Published As

Publication number Publication date
AU2022384375A1 (en) 2024-05-09
CN118176188A (zh) 2024-06-11
KR20240105380A (ko) 2024-07-05
EP4431503A1 (en) 2024-09-18
CA3237743A1 (en) 2023-05-19
TW202321204A (zh) 2023-06-01
US20260069725A1 (en) 2026-03-12
WO2023083209A1 (zh) 2023-05-19

Similar Documents

Publication Publication Date Title
JP2024544870A (ja) Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用
JP6661010B2 (ja) ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物
JP2021506784A (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
CN102911256B (zh) 一种放射性标记的多肽配合物及其制备方法和应用
KR101055700B1 (ko) 면역세포 영상화 및 탐지를 위한 양기능성킬레이트제와 만노실 인혈청알부민의 결합체 및 그의 방사성동위원소 표지 화합물
CN111905112A (zh) 靶向pd-l1的多肽复合物及其应用
WO2024064969A2 (en) High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
WO2026040780A1 (zh) 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
JP2025505467A (ja) ペプチド尿素誘導体、それを含む医薬組成物及びその使用
JP2024532521A (ja) ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用
TW202543589A (zh) 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用
JP7844752B2 (ja) Ｒｇｄ二量体化合物およびその調製方法と使用
CN107308466B (zh) 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用
JP7805170B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
JP2000507233A (ja) 新規の三元複合体放射性薬剤
CN118119581A (zh) 放射性药物、其生产方法以及在疾病治疗、诊断和成像中的用途
JP5774687B2 (ja) トリカルボニルテクネシウム−９９ｍまたはレニウム−１８８標識サイクリックＲＧＤ誘導体、その製造方法及びそれを有効成分として含む新生血管関連疾患の診断または治療用薬学的組成物
PL239934B1 (pl) Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
JP5604680B2 (ja) 放射性標識薬剤
EP4696686A1 (en) Fapi theranostic compounds assembled with tetrazine ligation
WO2025153101A1 (zh) 一种含氮化合物及其制备方法与用途
WO2024051794A1 (zh) 放射性核素偶联药物及其药物组合物和应用
KR101471891B1 (ko) DOTA 표지 글루코사민-함유 시클로 RGDfK 유도체, 그 제조방법 및 그것을 포함하는 핵의학 영상 조영제 및 암 치료제
CN120795028A (zh) 锝-99m标记含D-脯氨酸修饰的阿仑膦酸衍生物及制备方法和应用
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251106

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251106